The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: Laboratory markers of neurodegenerative diseases

Neurological Sciences

Volumn 30, Issue 1, 2009, Pages 1-7

  Mares, Jan ^a   Kanovsky, P ^a   Herzig, R ^a   Stejskal, D ^b   Vavrouskova, J ^b   Hlustik, P ^a   Vranova, H ^a   Burval, S ^a   Zapletalova, J ^c   Pidrman, V ^a   Obereigneru, R ^a   Suchy, A ^a   Vesely, J ^c   Podivinsky, J ^d   Urbanek, K ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b Sternberk Hospital   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d Neurology Geriatric Medical Institution   (Czech Republic)

Author keywords

Alzheimer dementia; Beta amyloid(1 42); CystatinC; Neurodegenerative diseases; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CYSTATIN C; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; RELIABILITY; ROC CURVE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CYSTATIN C; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; TAU PROTEINS; UP-REGULATION; YOUNG ADULT;

EID: 58249115299     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-008-0005-7     Document Type: Article

References (21)

1. Jellinger KA, Janetzky B, Attems J, Kienzl E (2008) Biomarkers for early diagnosis of Alzheimer Aisease: 'ALZheimer ASsociated gene': a new blood biomarker? J Cell Mol Med 12(4):1094-1117
2. Palm DE, Knuckey NW, Primianom J, Spangenberger AG, Johanson CE (1995) Cystatin C, a protease inhibitor, in degenerating rat hippocampal neurons following transient forebrain ischemia. Brain Res 691(1-2):1-8
3. Blennow K, Walin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231-245
4. Cathcart HM, Huang R, Lanham IS, Corder EH, Poduslo SE (2005) Cystatin C as a risk factor for Alzheimer disease. Neurology 64(4):755-757
5. Galteau m M, Guyon M, Gueguen R, Siest G (2001) Determination of serum cystatin C: Biological variation and reference values. Clin Chem Lab Med 39:850-857
6. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M (2007) Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 39(12):1437-1439
7. Beyer K, Lao JI, Gomez M, Riutort N, Latorre P, Mate JL, Ariza A (2001) Alzheimer' s disease and the cystatin C gene polymorphism: An association study. Neurosci Lett 315:17-20
8. Maruyama H, Izumi Y, Oda M, Torii T, Morino H, Toji H, Sasaki K, Terasawa H, Nakamura S, Kawakami H (2001) Lack of an association between cystatin C gene polymorphsms in Japanese patients with Alzheimer' s disease. Neurology 57:337-339
9. Gresser O, Weber E, Hellwig A, Riese S, Regnier-Vigouroux A (2001) Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the expression of active cathepsin L and cathepsin S. Eur J Immunol 31:1813-1824
10. Izumihara A, Ishihara T, Hoshii Y, Ito H (2001) Cerebral amyloid angiopathy associated with hemorrhage: Immunohistochemical study of 41 biopsy cases. Neurol Med Chir 41:471-477 Discussion 477-478
11. Miyake T, Gahara Y, Nakayama M, Yamada H, Uwabe K, Kitamura T (1996) Upregulation of cystatin C by microglia in the rat facial nucleus following axotomy. Brain Res Mol Brain Res 37:273-282
12. Katakai K, Shinoda M, Kabeya K, Wanatabe M, Ohe Y, Mori M, Ishikawa K (1997) Changes in distribution of cystatin C, apolipoprotein E and ferritin in rat hypothalamus after hypophysectomy. J Neuroendocrinol 9:247-253
13. Sveinbjornsdottir S, Blondal H, Gudmunsson G, Kjartansson O, Jonsdottir S (1996) Progressive dementia and leukoencephalopathy as the initial presentation of two cases. J Neurol Sci 140:101-108
14. Levy E, Jaskolski M, Grubb A (2006) The role of cystatin C in cerebral amyloid angiopathy and stroke: Cell biology and animal models. Brain Pathol 16(1):60-70
15. Rychlík I, Treŝlová L, Klepetár̂ J, Jaroŝ M, Havrda M, Paldusová J, Nováková H (2002) Cystatin c: Signification of sera values assessment by diabetic with nephropathy. Nefrol Suppl 1:8
16. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Igbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 52(8):1533-1534
17. Galasko D, Clarc C, Chang L, Miller B, Green RC, Motter R, Seubert P (1997) Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer disease. Neurology 48:632-635
18. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R (1995) Reduction of β amyloid peptide(1-42) in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 34:643-648
19. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58:349-350
20. Kalman J, Marki-Zay J, Juhasz A, Santha A, Dux L, Janka Z (2000) Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia. Acta Neurol Scand 101(4):279-282
21. Shimode K, Kobayashi S, Imaoka K, Umegae N, Nagai A (1996) Leukoencephalopathy-related cerebral amyloid angiopathy with cystatin C deposition. Stroke 27:1417-1419